|
Post by iamaverb on Aug 24, 2016 15:16:22 GMT
This has been a profitable stock for me and now it is moving quickly higher today.Could positive news be leaking out from the FDA?
|
|
|
Post by iamaverb on Sept 19, 2016 16:05:50 GMT
SRPT Sarepta jumped 86% today on FDA approval, and that is after jumpig 29% last week when the FDA critic that was opposing approval for the drug resigned, and today the FDA approved the drug. Hopefully this will be a "shake up call" to the FDA and they will relax their opposition to medical advancements, aka Ocata. I am up 211% but unfortunately I only own 1500 shares.
From Fidelity
Sarepta Therapeutics Inc. (SRPT) shares hurtled up as much as 82% in morning trade Monday after the Food and Drug Administration granted its Duchenne muscular dystrophy drug - the first treatment for the degenerative disease - accelerated approval. The drug, eteplirsen, has had an unusually long and controversial history with the FDA. An agency advisory committee voted earlier this year, but the agency then about approval, which was expected months ago. News of a prominent critic of the drug departing from the FDA last week again about a possible approval. Duchenne muscular dystrophy, which mostly affects boys, typically kills patients before the age of 30. Patients and their families were particularly outspoken advocates for the approval of eteplirsen, pushing back against the agency's concerns at meetings open to the public. Sarepta shares rose 160.7% over the last three months, compared with a 3.9% rise in the S&P 500 .
|
|
|
Post by JHam on Sept 20, 2016 16:20:52 GMT
SRPT Sarepta jumped 86% today on FDA approval, and that is after jumpig 29% last week when the FDA critic that was opposing approval for the drug resigned, and today the FDA approved the drug. Hopefully this will be a "shake up call" to the FDA and they will relax their opposition to medical advancements, aka Ocata. I am up 211% but unfortunately I only own 1500 shares. From Fidelity Sarepta Therapeutics Inc. (SRPT) shares hurtled up as much as 82% in morning trade Monday after the Food and Drug Administration granted its Duchenne muscular dystrophy drug - the first treatment for the degenerative disease - accelerated approval. The drug, eteplirsen, has had an unusually long and controversial history with the FDA. An agency advisory committee voted earlier this year, but the agency then about approval, which was expected months ago. News of a prominent critic of the drug departing from the FDA last week again about a possible approval. Duchenne muscular dystrophy, which mostly affects boys, typically kills patients before the age of 30. Patients and their families were particularly outspoken advocates for the approval of eteplirsen, pushing back against the agency's concerns at meetings open to the public. Sarepta shares rose 160.7% over the last three months, compared with a 3.9% rise in the S&P 500 . It is at $55 at the moment. That is a very nice chunk of cash. Congrats!
|
|
|
Post by iamaverb on Sept 20, 2016 18:13:29 GMT
SRPT Sarepta jumped 86% today on FDA approval, and that is after jumpig 29% last week when the FDA critic that was opposing approval for the drug resigned, and today the FDA approved the drug. Hopefully this will be a "shake up call" to the FDA and they will relax their opposition to medical advancements, aka Ocata. I am up 211% but unfortunately I only own 1500 shares. From Fidelity Sarepta Therapeutics Inc. (SRPT) shares hurtled up as much as 82% in morning trade Monday after the Food and Drug Administration granted its Duchenne muscular dystrophy drug - the first treatment for the degenerative disease - accelerated approval. The drug, eteplirsen, has had an unusually long and controversial history with the FDA. An agency advisory committee voted earlier this year, but the agency then about approval, which was expected months ago. News of a prominent critic of the drug departing from the FDA last week again about a possible approval. Duchenne muscular dystrophy, which mostly affects boys, typically kills patients before the age of 30. Patients and their families were particularly outspoken advocates for the approval of eteplirsen, pushing back against the agency's concerns at meetings open to the public. Sarepta shares rose 160.7% over the last three months, compared with a 3.9% rise in the S&P 500 . It is at $55 at the moment. That is a very nice chunk of cash. Congrats! What has happened with Sarepta is what many of us were hoping for ACTC/OCAT. There is even talk of a buyout by Big Pharma, ala Caesar, speaking of which, even a broken clock is right twice a day, something that eluded Caesar. Now my risk averse stocks hinging on the FDA are ADXS, and to a lesser degree EDIT and NTLA.
|
|
|
Post by iamaverb on Sept 21, 2016 20:22:58 GMT
SRPT announced after the market closed that they want to sell 225 million dollars in stock to fund forward development. This is the perfect time to offer the shares after the stock has gained 400% since February, 100% in the last week. The stock is up slightly in after hours.
|
|
|
Post by iamaverb on Oct 6, 2016 23:00:57 GMT
News aftermarket. Expect to see a jump in the price in the a.m.
Sarepta Therapeutics' Duchenne Muscular Dystrophy Drug To be Covered by Humana MIDNIGHT TRADER 2:41 PM ET 6/10/2016 Symbol Last Price Change SRPT 61.74down -0.61 (-0.98%) QUOTES AS OF 04:00:00 PM ET 06/10/2016 03:41 PM EDT, 10/06/2016 (MT Newswires) -- Shares of Sarepta Therapeutics(SRPT) were trading higher earlier on Thursday after a tweet from a mother who sons have Duchenne muscular dystrophy claimed Humana Insurance (HUM) has approved 100% coverage for Serepta's Exondys51.
Exondys51, formally called Eteplirsen, is Serepta's experimental drug to treat the rare form of childhood muscular dystrophy. On Srpt 19 the U.S. Food and Drug Administration granted accelerated approval to Exondys51. Since then, shares have skyrocketed 127%.
The drug, however, could cost approximately $300,000 per year, the typical price tag for a treatment for a rare disease.
SRPT last traded fractionally lower at $62.05, near the high of its 52-week range of $8.00 to $63.73.
Price: 61.90, Change: -0.45, Percent Change: -0.73
|
|